Phase II
For type 1 narcolepsy, this sleep-wake instability is linked to low levels of hypocretin, also called orexin. Hypocretin is a neurotransmitter produced in the hypothalamus and has a significant role in wakefulness and regulating rapid eye movement (REM) sleep. But Harmony Biosciences has found another link, this one to histamine.
Something that most everyone does multiple times a day may not be as care-free as initially thought. Taking a selfie with a smart phone can actually be harmful to your skin.
Researchers at Massachusetts General Hospital in Boston published results from a long-term clinical trial of a tuberculosis vaccine in type 1 diabetes patients that in a long-term follow-up appears to have cured the disease.
Sarepta Therapeutics shares rocketed by as much as 80 percent yesterday after the company released interim data on its experimental gene therapy AAVrh74.MHCK7.micro-Dystrophin for Duchenne muscular dystrophy (DMD).
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
PTC Therapeutics presented updated interim clinical data from Part 1 of its FIREFISH clinical trial of risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy.
Shares of Solid Biosciences have jumped 11 percent in premarket trading after the company announced the U.S. Food and Drug Administration has lifted a clinical hold on the company’s Phase I/II clinical trial gene therapy treatment for Duchenne muscular dystrophy (DMD).
Cytokinetics released data from its Phase II clinical trial of reldesemtiv in patients with spinal muscular atrophy (SMA).
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.
PRESS RELEASES